Piedimonte Sabrina, Richer Lara, Souhami Luis, Arseneau Jocelyne, Fu Lili, Gilbert Lucy, Alfieri Joanne, Jardon Kris, Zeng Xing Ziggy
Department of Obstetrics and Gynecology, McGill University Health Center, Montreal, Canada.
Department of Pathology, McGill University Health Center, Montreal, Canada.
J Surg Oncol. 2018 Dec;118(7):1194-1198. doi: 10.1002/jso.25259. Epub 2018 Oct 24.
Ultrastaging in endometrial cancer (EC) led to increased detection of isolated tumor cells (ITC, ≤0.2 mm) and micrometastases (MM, 0.2-2 mm), with unclear effect on prognosis. Our aim was to characterize the impact of ITC and MM on the outcome of these patients.
Grade 1 to 2 stage I endometrioid EC patients with nodal ITC (n = 11) or MM (n = 12) between 2012 and 2018 were retrospectively compared to a matched group of lymph node negative (n = 18) patients based on age, body mass index, grade, myometrial invasion, and lymphovascular space invasion (LVI) status using propensity score analysis (1:1). Mann-Whitney U tests were performed on continuous variables and χ tests on categorical variables. Progression-free survival (PFS) was the main endpoint.
All MM and 81% of ITC had LVI. More ITC/MM patients received RT and chemotherapy (91.7% vs 18.4%; 70.8% vs 4.5%, respectively; P < 0.01) without significant difference in treatment-related toxicities (25% vs 27.3% grade 1%-2% and 20.8% vs 9.1% grade 2-3; P = 0.538) or PFS (29.2 vs 25 months; P = 0.828). Two distant recurrences occurred in MM patients after 2.5 years; one lung and one para-aortic lymph node.
With adjuvant treatment, ITC/MM in otherwise well-differentiated stage I endometrial cancer have similar outcomes to matched LN- patients.
子宫内膜癌(EC)的超分期导致孤立肿瘤细胞(ITC,≤0.2毫米)和微转移灶(MM,0.2 - 2毫米)的检出率增加,但其对预后的影响尚不清楚。我们的目的是明确ITC和MM对这些患者预后的影响。
对2012年至2018年间患有淋巴结ITC(n = 11)或MM(n = 12)的1至2级I期子宫内膜样EC患者,基于年龄、体重指数、分级、肌层浸润和淋巴血管间隙浸润(LVI)状态,使用倾向评分分析(1:1)与一组匹配的淋巴结阴性(n = 18)患者进行回顾性比较。对连续变量进行曼 - 惠特尼U检验,对分类变量进行χ检验。无进展生存期(PFS)是主要终点。
所有MM和81%的ITC都有LVI。更多的ITC/MM患者接受了放疗和化疗(分别为91.7%对18.4%;70.8%对4.5%;P < 0.01),在治疗相关毒性(1% - 2%为1级的患者中分别为25%对27.3%,2 - 3级的患者中分别为20.8%对9.1%;P = 0.538)或PFS(29.2对25个月;P = 0.828)方面无显著差异。MM患者在2.5年后发生了两例远处复发;一例肺部复发和一例主动脉旁淋巴结复发。
通过辅助治疗,在其他方面分化良好的I期子宫内膜癌中的ITC/MM与匹配的淋巴结阴性患者具有相似的预后。